The United States is the world's largest pork producer (~125M pigs/year) and exports the porcine intestinal mucosa to China for processing into the active ingredient in every dose of heparin sold in U.S. hospitals. China supplies 60–80% of U.S. heparin API. The 2008 contamination event killed 81 Americans. The 18-year-old white space remains unfilled. Federal funding architecture under EO 14336 and BARDA BioMaP is now mature.
Sold once to one buyer. Once purchased, this thesis leaves the catalog permanently.
Secured by Stripe. Your purchase includes the thesis PDF, 10-sheet fact sheet (xlsx), three production charts (PNG), 30 days of analyst follow-up, and one 60-minute call.
| China share of U.S. heparin API supply | 60–80% |
|---|---|
| 2008 OSCS contamination — U.S. deaths confirmed | 81 |
| U.S. pigs slaughtered annually | ~125 million |
| Global heparin market (2024) | $5.4B – $10.0B |
| Forecast market size by 2030 | $10.5B – $14.2B |
| North America regional share | ~38.6% of global |
| Indicative project CapEx | $40M – $80M |
| Time to first revenue | 30 – 42 months |
| BARDA BioMaP RPP ceiling per project | $200M |
| ISR aggregate score | 22 / 25 |
346 paragraphs of analyst-grade narrative: strategic context, market structure, demand drivers, technical feasibility, competitive landscape, federal funding stack, capital stack and unit economics, key personnel, regulatory pathway, comparable transactions, risk factors, and investment recommendation. Four appendices.
Structured xlsx with every data point cited in the thesis: USGS-equivalent FDA Drug Master File records, supply chain concentration, market size and pricing, policy timeline, federal funding stack, competitive landscape, end-use demand, regulatory, sources (25 numbered citations), and modeling assumptions.
Print-ready 300 DPI PNG charts: U.S. heparin supply chain geographic source by stage, global market forecast convergence across five analyst sources, and 18-year policy/risk chronology from BSE bovine discontinuation to BARDA BioMaP solicitation.
One of the three production charts included with the thesis. China processes the porcine mucosa exported from U.S. slaughterhouses; the dependency lives in the upstream extraction step — where this thesis identifies the white-space opportunity.
August 13, 2025 directs ASPR to stockpile 6-month supply for 26 critical drugs + 86 essential medicines, prioritizing U.S.-made ingredients.
February 2026 solicitation authorizing up to $200M per project for Antimicrobials and Large Volume Parenterals — heparin is exactly that category.
Shenzhen Hepalink expanded crude heparin API by 40 metric tons/year (March 2024). The dependency is deepening, not diversifying.
The 2008 contamination response produced enhanced import testing, not domestic capacity. The 18-year white space remains unfilled.
ISR-001 is the inaugural thesis in the Industrial Spine Research catalog. It is sold once, to one institutional buyer — typically a private equity firm, family office, defense prime with reshoring mandate, or pharmaceutical CDMO sponsor evaluating SAPIR procurement opportunities. The buyer receives complete exclusive access including 30 days of analyst follow-up and one 60-minute call.
Once a thesis is sold, it leaves the catalog permanently. The next pharmaceutical-pillar thesis — currently in research — will be vancomycin HCl API or iodinated contrast media. Methodology subscribers receive 30-day first-look access on new theses before public catalog listing.